Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been presented as novel pharmacological therapy for patients with heart failure (HF), showing reductions in hospitalization for HF and mortality in multiple randomized controlled trials [1–5]. The gene discussed is SLC5A2; the disease is heart failure.